Skip to main content

Table 3 Sentiment orientation of comments for six drugs

From: A comment-driven evidence appraisal approach to promoting research findings into practice when only uncertain evidence is available

Drugs

WHO guideline date

Recommendation sentences

Recommend using?

Sentiment orientations (%)

Positive

Negative

Neutral

Corticosteroids

2 September 2020 (Version 1)

“A strong recommendation for systemic corticosteroid (severe patients)”

“A conditional recommendation against corticosteroid (non-severe patients)”

Yes

28 (50.00%)

12 (21.43%)

16 (28.57%)

IL-6

6 July 2021 (Version 5)

“A strong recommendation to use IL-6 receptor blockers (tocilizumab or sarilumab) in severe or critical patients”

Yes

48 (50.00%)

25 (26.04%)

23 (23.96%)

HCQ

17 December 2020 (Version 3)

“A strong recommendation against the use of hydroxychloroquine”

No

62 (32.63%)

94 (49.47%)

34 (17.89%)

Remdesivir

20 November 2020 (Version 2)

“A conditional recommendation against the use of remdesivir for patients with COVID-19”

No

19 (29.23%)

30 (46.15%)

16 (24.62%)

LPV/r

17 December 2020 (Version 3)

“A strong recommendation against the use of lopinavir/ritonavir”

No

9 (20.93%)

25 (58.14%)

9 (20.93%)

Ivermectin

31 March 2021 (Version 4)

“A strong recommendation to use IL-6 receptor blockers (tocilizumab or sarilumab) in severe or critical patients”

No

4 (30.77%)

7 (53.85%)

2 (15.38%)